Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,042.21 +27.00 (+2.66%)
Streaming Delayed Price Updated: 12:02 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Healthcare’s Renaissance: Sector Outshines Tech as Policy Clarity Sparks Q4 Surge
The healthcare sector has staged a dramatic structural breakout, ending a multi-year period of relative stagnation to lead the global markets into 2026. After a powerful 10% gain in the final quarter... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
Goldman Sachs Predicts 12% S&P 500 Rally in 2026: Five Key Themes for the "Marathon" Bull Market
As the global economy stabilizes into a period of disinflationary growth, Goldman Sachs (NYSE: GS) has released a robust 2026 stock market outlook, forecasting a 12% total return for the S&P 500. This... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know. ↗
Both companies are betting on interest in weight loss pills. 
Via The Motley Fool
News headline image
1 Cash-Producing Stock with Competitive Advantages and 2 That Underwhelm
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
News headline image
I Predicted That ExxonMobil Would Join the $1 Trillion Club by 2030, But the Stock Is Already Up 24% in 2026. Is the High-Yield Dividend Stock Still a Buy Now? ↗
Energy stocks are in the spotlight, and ExxonMobil is best in breed. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline ↗
The company shared optimistic timelines for advancing the clinical studies of both oral and subcutaneous VK2735 in obesity. 
Via Stocktwits
News headline image
Novo Nordisk Reportedly Eyes Launching Wegovy In Vials To Compete With Rival Eli Lilly ↗
Bloomberg reported on Wednesday, citing Novo CEO Mike Doustdar, that the vials are slated to be introduced in the U.S. this year. 
Via Stocktwits
Topics Intellectual Property
News headline image
3 Reasons to Buy Eli Lilly Stock ↗
The healthcare leader looks increasingly unstoppable. 
Via The Motley Fool
Topics Government
News headline image
Disney Has Its Next CEO ↗
Disney has hired a new CEO, with Josh D'Amaro taking over for Bob Iger in March. 
Via The Motley Fool
News headline image
Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip. ↗
Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks. 
Via The Motley Fool
News headline image
Biotech Beat Nvidia in 2025. Can It Do It Again? ↗
Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they help the industry once again outperform AI champ Nvidia? 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss
As of February 11, 2026, Incyte Corporation (NASDAQ: INCY) finds itself at a pivotal crossroads. Known for over a decade as a one-drug powerhouse centered on the hematology blockbuster Jakafi, the... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore ↗
This stock has been known to soar after good news. 
Via The Motley Fool
News headline image
The Top 5 Analyst Questions From Eli Lilly’s Q4 Earnings Call
Eli Lilly's fourth quarter performance was defined by accelerating demand for its obesity and diabetes medicines, as well as rapid uptake in international markets. Management highlighted the strong... 
Via StockStory
Topics Earnings
News headline image
Zoetis (ZTS) Reports Q4: Everything You Need To Know Ahead Of Earnings
Animal health company Zoetis (NYSE:ZTS) will be announcing earnings results this Thursday morning. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
News headline image
Organon Earnings: What To Look For From OGN
Pharmaceutical company Organon (NYSE:OGN) will be announcing earnings results this Thursday morning. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗
Could these two companies be biotech giants in the making? 
Via The Motley Fool
News headline image
2 Vanguard ETFs That Could Turn $400 Per Month Into $1 Million ↗
These exchange-traded funds invest in some of the best growth stocks in the world. 
Via The Motley Fool
Topics ETFs
News headline image
Thinking About Investing in GLP-1 Stocks? Here Are 3 Things You Need to Know ↗
The GLP-1 market is a massive opportunity in healthcare, and many companies are vying for a piece of it. 
Via The Motley Fool
News headline image
AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse
On February 10, 2026, AstraZeneca (NYSE:AZN) delivered an earnings report that did more than just recap a successful fiscal year; it laid down a definitive challenge to the current titans of the... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
The $80 Billion Ambition: An In-Depth Analysis of AstraZeneca (AZN) in 2026
Date: February 10, 2026 Introduction AstraZeneca PLC (NASDAQ: AZN; LSE: AZN) stands today at a critical crossroads of pharmaceutical history. Long recognized as the crown jewel of British... 
Via Finterra
Topics Artificial Intelligence Economy Fraud
News headline image
Hoth Therapeutics's GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial ↗
The company announced positive preclinical results from a study evaluating GDNF as a potential treatment for obesity and metabolic-associated steatotic liver disease. 
Via Stocktwits
News headline image
The Vertical Integration of Wellness: A Deep Dive into Hims & Hers Health (HIMS)
Today is February 10, 2026. The telehealth landscape stands at a historic inflection point, and no company better embodies this volatility than Hims & Hers Health, Inc. (NYSE: HIMS). After a meteoric... 
Via Finterra
Topics Artificial Intelligence Intellectual Property Lawsuit
News headline image
Eli Lilly Is Partnering with Gene-Editing Start-up Seamless Therapeutics. Here's What Investors Need to Know. ↗
Eli Lilly is flying high thanks to its success in the GLP-1 space, but what comes next? 
Via The Motley Fool
Topics Intellectual Property
News headline image
Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains? ↗
The stock has climbed in the triple digits over the past three years. 
Via The Motley Fool
News headline image
What To Expect From Royalty Pharma’s (RPRX) Q4 Earnings
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting results this Wednesday morning. Here’s what to expect. 
Via StockStory
Topics World Trade
News headline image
Novo Nordisk vs. Eli Lilly: What's the Better Long-Term Investment? ↗
These stocks have been going in opposite directions of late, but that doesn't mean that trend will continue. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Over 60% of Eli Lilly's Revenue Comes From Its GLP-1 Drugs. Should Investors Be Worried? ↗
Mounjaro and Zepbound generated a combined $11.7 billion in sales for the company in its most recent quarter. 
Via The Motley Fool
News headline image
The GLP-1 Gold Rush Hits a Wall: Novo Nordisk Sues Hims & Hers as FDA Crackdown Triggers 20% Stock Crash
The multi-billion dollar weight-loss drug market experienced a seismic shift this morning as the era of easy-access compounded alternatives faced its most significant legal and regulatory challenge to... 
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
Why Eli Lilly Stock Just Popped ↗
Novo Nordisk just did Eli Lilly stock a huge favor. 
Via The Motley Fool
Topics Lawsuit
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.